Because of the high selectivity of nanocarrier to IDO1-overexpressed tumor cells, significant in vitro cytotoxicity and superior antitumor effects (Fig. 6a-IV) were acquired, providing a promising platform for accurate intracellular drug release. This evidence concerns the gene IDO1 and neoplasm.